Global Cancer News

Antibodies to a retina protein to be used as a kidney cancer marker

Tumors can be benign or malignant. Benign tumors can evolve into malignant ones. Around 90 to 93% of all kidney growths turn out to be malignant, and there are currently no effective methods for early diagnostics. The initial stages of kidney cancer have no signs or specific symptoms, so patients are often diagnosed with kidney cancer when it has already metastasized. At this point, the doctors make prognosis not about the possibility of recovery, but about a patient’s life expectancy. Sechenov University researchers and German colleagues report a highly sensitive, painless method for diagnosing kidney cancer. This method is based on measuring of the immune response to arrestin-1, a retina protein that is synthesized in the cancerous cells of kidneys.

To read more, please click here.